CN113559141B - Application of artemisia capillaris for preparing medicine for treating pulmonary fibrosis - Google Patents

Abstract

The invention discloses application of artemisia capillaris for preparing a medicine for treating pulmonary fibrosis.

Description

Use of Artemisia annua in preparing medicine for treating pulmonary fibrosis

technical field

The invention relates to the use of Artemisia annua for preparing medicine for treating pulmonary fibrosis.

Background technique

Pulmonary fibrosis is a chronic inflammatory interstitial lung disease of unknown cause, such as interstitial pneumonia and lung diseases caused by connective tissue. In recent years, the incidence of pulmonary fibrosis is on the rise, with a high fatality rate and serious harm to human health. The main clinical manifestations of pulmonary fibrosis patients are progressive dyspnea, which eventually develops into hypoxemia and respiratory failure and death. The average survival time after diagnosis is 3 years. The pathogenesis of pulmonary fibrosis is complex, the mechanism is unknown, and there is still a lack of effective therapeutic drugs. At present, the clinical treatment of pulmonary fibrosis is mainly based on immunosuppressive drugs and glucocorticoid drugs, but the efficacy is not obvious and the side effects are not obvious.

Artemisia capillaris Thunb. (scientific name: Artemisia capillaris Thunb.) is a semi-shrub-like herb of the family Compositae, and the plant has a strong aroma. Artemisia annua is rich in vitamins, various trace elements and more than 20 kinds of amino acids needed by the human body, and has good health care functions. The most famous one is Yinchenhao Decoction for treating diseases. In Treatise on Febrile Diseases, Yin Chenhao Decoction is mainly used to treat "yellowing" caused by "stagnation of heat in the interior" of Yangming disease, while in "Golden Chamber Yaolue Fang Lun", it is used to treat jaundice. "Gluten Jaundice". Later generations of medical families mainly used Yinchenhao Decoction to treat damp-heat jaundice. Today, Yinchenhao Decoction is more often used to treat infectious hepatitis, and on the basis of this recipe, the herbs are often added or removed, and it is widely used in the clinical treatment of hepatobiliary diseases.

There are also studies reporting that Artemisia annua is used in combination with other traditional Chinese medicines for the treatment of lung cancer. CN108524841A discloses a medicine for treating lung cancer. Including Houttuynia cordata, Paeonia suffruticosa, Prunella, Agrimony, Ligusticum comfrey, Oyster, Fore Hu, Ligustrum lucidum, Curcuma, Dodder, Hedyotis diffusa, Chuan Neem, North American ginseng, Artemisia annua, Bai Bu, Ophiopogon japonicus, Tinglizi, lily, orange pit, yam, aster, reed root, seaweed, mulberry bark, Rhizoma Imperatae, donkey-hide gelatin, Xu Changqing and Wang Buliuxing are prepared in a certain weight ratio.

Artemisia scoparia is the dry seedling of Artemisia scoparia Waldst.et Kit. or Artemisiacapillaris Thunb. of Compositae. Yinchen was first recorded in "Shen Nong's Materia Medica". "Mainly rheumatism, cold and heat evil, heat causes jaundice" Mongolian medicine Arong is currently included in the "Inner Mongolian Mongolian Medicinal Materials Standard", also known as Yinchen. Arong can be used alone or in combination with other Mongolian medicines. Used alone, it can clear the lung, relieve cough, and dry lung pus.

CN102552663A discloses a traditional Chinese medicine compound for treating paraquat poisoning, including gecko, cordyceps, star anise, Chuanbei, Yinchen, calamus, cassia twig, white peony, loofah, Eclipta, black plum, ginseng, donkey-hide gelatin , stove heart soil. Although the patent document mentions that the traditional Chinese medicine compound is supported by traditional Chinese medicine treatment theories such as promoting blood circulation and removing blood stasis, removing rot and promoting muscle, nourishing the lung and dredging collaterals, protecting the liver and protecting the kidney, etc. Formed, but the patent document is to use the synergy of traditional Chinese medicine to treat paraquat poisoning.

To sum up, there is no relevant report on the use of Artemisia annua as the main active ingredient in the preparation of medicines for the treatment of pulmonary fibrosis.

SUMMARY OF THE INVENTION

The purpose of the present invention is to provide the use of Artemisia annua for preparing a medicine for treating pulmonary fibrosis. Artemisia annua can significantly increase the content of SOD, significantly reduce the content of MDA, and to a certain extent can increase the content of GSH. The object of the present invention is achieved through the following technical solutions.

The invention provides the use of Artemisia annua for preparing medicine for treating pulmonary fibrosis.

According to the use of the present invention, preferably, the Artemisia annua is a medicinal powder of Artemisia annua or an Artemisia annua extract.

According to the use of the present invention, preferably, the Artemisia annua is an Artemisia annua extract.

According to the use of the present invention, preferably, the drug forms a pharmaceutical preparation for treating pulmonary fibrosis, the pharmaceutical preparation comprises Artemisia annua and pharmaceutically acceptable excipients.

According to the use of the present invention, preferably, the Artemisia annua is the only active ingredient in the medicine for treating pulmonary fibrosis.

According to the use according to the present invention, preferably, the medicament forms a pharmaceutical preparation for increasing the level of SOD in serum.

According to the use according to the present invention, preferably, the medicament forms a pharmaceutical preparation for reducing the content of MDA in serum.

According to the purposes of the present invention, preferably, the Artemisia annua extract is prepared by comprising the following steps:

Soak the sieved Artemisia annua medicinal powder in water, heat and reflux for extraction 2 to 5 times, combine the water extracts, separate solid-liquid, and concentrate to obtain Artemisia annua extract; wherein, the amount of water each time is sieved. 8-16 times the quality of the powder of Artemisia annua L., the soaking time is 2-6 hours each time, and the extraction time is 2-6 hours each time.

According to the use of the present invention, preferably, in a unit dose of the pharmaceutical preparation, the dosage of Artemisia annua L. extract is 0.89-4.6 g.

According to the use of the present invention, preferably, the dosage of Artemisia annua L. extract is 1.8-4.3 g.

The Artemisia annua of the present invention is used for preparing a medicine for treating pulmonary fibrosis, and it is found in the research of the present invention that Artemisia annua can interfere with the rat pulmonary fibrosis model established by tracheal instillation of bleomycin. Inflammatory cell infiltration, alveolar septum thickening, fibroblast hyperplasia and collagen deposition were improved after Artemisia annua administration. Artemisia annua can significantly increase the content of SOD, significantly reduce the content of MDA, and to a certain extent can increase the content of GSH.

Description of drawings

Figure 1 shows the effect of different dosages of Artemisia annua on HE staining of bleomycin-induced pulmonary fibrosis in rats.

Figure 2 shows the effect of different dosages of Artemisia annua on Masson staining in bleomycin-induced pulmonary fibrosis rats.

Figure 3 is the result of detecting the content of SOD in rat serum in each group.

Figure 4 shows the results of detecting the content of GSH in rat serum in each group.

Figure 5 shows the results of detecting the content of MDA in rat serum in each group.

In Figures 1 to 5, CON represents the normal control group, MOD represents the model control group, ASL represents the Artemisia annua low-dose group (100 mg/kg), ASM represents the Artemisia annua mid-dose group (200 mg/kg), and ASH represents the Artemisia annua Chenhao high dose group (400mg/kg), PRE represents the positive control group.

Detailed ways

The present invention will be further described below with reference to specific embodiments, but the protection scope of the present invention is not limited thereto.

The use of Artemisia annua of the present invention for preparing a medicine for treating pulmonary fibrosis.

In the present invention, Artemisia annua can be a medicinal material of Artemisia annua, such as Artemisia annua medicinal powder. Artemisia annua may be Artemisia annua extract.

According to a preferred embodiment of the present invention, Artemisia annua is an extract of Artemisia annua.

The preparation method of Artemisia annua extract is not particularly limited. According to one embodiment of the present invention, the Artemisia annua extract is prepared by the following steps: heating and refluxing the sieved Artemisia annua medicinal powder with water for 2 to 5 times, merging the water extracts, solid-liquid separation, Concentrating to obtain Artemisia annua extract; wherein, the amount of water each time is 8 to 16 times the quality of the sieved Artemisia annua medicinal powder, and the extraction time is 2 to 6 hours each time.

In the present invention, heating and reflux extraction may be performed 2 to 5 times, preferably 2 to 4 times of heating and reflux extraction, and more preferably 3 to 4 times. During each extraction, the amount of water used can be 8-16 times, preferably 8-13 times, and more preferably 9-11 times the mass of the sieved Artemisia annua medicinal material powder. The time of each extraction can be 2-6 hours, preferably 3-6 hours, more preferably 2-5 hours.

In the present invention, the Artemisia annua medicinal material can be crushed first and then passed through a No. 2 sieve. Before each extraction, soak the sieved Artemisia annua medicinal powder in water for 2-6 hours, preferably 3-6 hours, more preferably 3-5 hours. This is beneficial to extract the desired Artemisia annua extract to a greater extent. According to a specific embodiment of the present invention, the medicinal materials of Artemisia annua are crushed and passed through a No. 2 sieve, the sieved Artemisia annua medicinal powder is soaked in water, heated and refluxed for 2 to 5 times of extraction, and solid-liquid separation is performed; combined water extraction The liquid and concentrated to obtain Artemisia annua extract; wherein, the amount of water each time is 8 to 16 times the mass of the sieved Artemisia annua medicinal powder, the soaking time is 2-6 hours each time, and the extraction time is 2-6 hours each time. For 2 ~ 6h. In the present invention, the solid-liquid separation can be filtration, and the filtration can be performed with multiple layers of gauze, such as three layers of gauze. In the present invention, the obtained Artemisia annua extract is substantially free of water. The obtained Artemisia annua extract is refrigerated at 4-6° C., and can be diluted and dissolved by adding water during use.

In the present invention, the drug forms a pharmaceutical preparation for treating pulmonary fibrosis, and the pharmaceutical preparation comprises Artemisia annua and pharmaceutically acceptable excipients.

In the present invention, Artemisia annua may be the only active ingredient in the medicine for treating pulmonary fibrosis. In certain embodiments, the drug for the treatment of pulmonary fibrosis has Artemisia annua as the only active ingredient. In other embodiments, the drug for treating pulmonary fibrosis may also contain other active ingredients that have the effect of treating pulmonary fibrosis, or contain other active ingredients that do not have the effect of treating pulmonary fibrosis, but can assist Artemisia annua to play the effect of treating pulmonary fibrosis. Active ingredient.

The medicament of the present invention can form a pharmaceutical preparation for significantly increasing the content of SOD in serum, and to a certain extent, increase the content of GSH in serum. Furthermore, the medicament of the present invention forms a pharmaceutical preparation for reducing the content of MDA in serum. SOD is superoxide dismutase. GSH is reduced glutathione. MDA is malondialdehyde.

SOD is an antioxidant metalloenzyme existing in organisms, which can catalyze the disproportionation of superoxide anion free radicals to generate oxygen and hydrogen peroxide, and plays a crucial role in the balance of oxidation and antioxidants in the body. GSH, the chemical name is N-(NL-γ-glutamyl-L-cysteinyl)glycine, the molecular formula is C ₁₀ H ₁₇ N ₃ O ₆ S, and the molecular weight is 307.33. MDA is a degradation product of lipid peroxidation, and its content can reflect the degree of lipid peroxidation in the body, and indirectly reflect the severity of cell or body damage.

In the present invention, the drug for treating pulmonary fibrosis may be a raw material drug or a preparation. The dosage form of the preparation can be any pharmaceutical dosage form, and is not particularly limited. Preferably, the dosage form is an oral dosage form. The oral dosage form can be a sustained-release or controlled-release dosage form, such as a sustained-release capsule, a sustained-release tablet, and the like. For example, the dosage forms are tablets, pills, capsules, granules, suspensions, and the like.

In certain embodiments, the drug for treating pulmonary fibrosis may comprise pharmaceutically acceptable excipients. The types of the pharmaceutically acceptable excipients are not limited. When the drug is an oral preparation, the adjuvant can be selected from one or more of diluents, binders, disintegrants and lubricants. The diluent includes but is not limited to one or more of mannitol, microcrystalline cellulose, lactose, sucrose, pregelatinized starch or dextrin, preferably one of microcrystalline cellulose, lactose or dextrin or more. The binder is selected from one of methyl cellulose, sodium carboxymethyl cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, gelatin, povidone or polyethylene glycol. one or more, preferably one or more of sodium carboxymethylcellulose, gelatin or povidone. The disintegrant includes, but is not limited to, one or more of sodium carboxymethyl starch, croscarmellose sodium, and crospovidone. The lubricant is selected from one or more of polyethylene glycol, sodium lauryl sulfate, talc or magnesium stearate, preferably crospovidone or croscarmellose sodium. According to an embodiment of the present invention, the excipients in the medicine comprise microcrystalline cellulose, sodium carboxymethyl cellulose and crospovidone.

In the present invention, in a unit dose of the pharmaceutical preparation, the dosage of Artemisia annua L. extract is 0.89-4.6 g, preferably 1.8-4.3 g, more preferably 1.95-4.1 g. According to a specific embodiment of the present invention, in a unit dose of the pharmaceutical preparation, the amount of Artemisia annua L. extract is 1.92-3.9 g. In the prepared medicine for treating pulmonary fibrosis, when the dosage of Artemisia annua is within the above range, it is convenient to take and exert its effect, and side effects are reduced.

The efficacy of the drug for treating pulmonary fibrosis in the present invention can reduce collagen fibers in the interstitium. It can significantly increase the content of SOD, significantly reduce the content of MDA, and increase the content of GSH to a certain extent.

Preparation example

After crushing the Artemisia annua medicinal material, pass it through a No. 2 sieve to obtain the sieved Artemisia annua medicinal material powder; soak 100 g of the sieved Artemisia annua medicinal material powder in water, and heat and reflux for extraction 3 times; the amount of water each time is: 1000mL, soaked for 5h each time, and heated and refluxed for extraction for 4h each time; the combined extracts were filtered and concentrated under reduced pressure to obtain 19.1g of Artemisia annua extract. Put it in the refrigerator at 4°C, and add water to dissolve it when using. Artemisia annua was provided by the Affiliated Hospital of Inner Mongolia University for Nationalities, Tongliao, Inner Mongolia.

Example 1

1. Animal modeling and experimental methods

Animals were healthy SD rats, weighing 300-350 g, purchased from Changchun Yisi Laboratory Animal Technology Co., Ltd.

The rats were randomly divided into normal control group, bleomycin model control group (model control group), Artemisia annua administration group (low, middle and high doses, and the dosage of Artemisia annua L. extract was 100 mg/kg and 200 mg, respectively. /kg, 400 mg/kg, Artemisia annua extract was obtained in the preparation example) and the positive control group of prednisone hydrochloride (5 mg/kg), a total of 6 groups with 10 animals in each group. Each group was given the corresponding test drug by intragastric administration, once a day, until sacrificed, and the model control group and the normal control group were intragastrically administered with distilled water. Except for the normal control group, the other groups were given a one-time injection of bleomycin 5 mg/kg into the trachea to build a rat pulmonary fibrosis model; the normal control group was given a one-time injection of the same volume of normal saline into the trachea. Rats were sacrificed on the 14th day after modeling, and lung tissue and blood were collected for subsequent experiments.

2. Observation indicators and their measurement methods

HE and Masson staining of lung tissue: The right posterior lobe of the rat lung was fixed in neutral formalin solution, and the conventional paraffin-embedded sections were subjected to HE staining and Masson staining to evaluate the damage of lung tissue and the degree of pulmonary fibrosis.

2.1 Tissue paraffin embedding and sectioning

2.1.1 The right posterior lobe of each group was taken out and fixed in 4% paraformaldehyde for 24 hours;

2.1.2 Aspirate the paraformaldehyde, add PBS solution (phosphate buffered saline) to soak, replace it every 8 hours, keep it for 72 hours continuously, and store it at 4°C;

2.1.3 Open the oven, set the temperature at 62°C, and dissolve the paraffin;

2.1.4 Cut each lung tissue into small pieces of 0.2-0.3 cm, and then dehydrate with alcohol gradient (the concentration of alcohol is 30%, 50%, 70%, 80%, 90%, 95%, 100%), Replace every 30min;

2.1.5 Put in 50% alcohol + 50% xylene solution for 30 minutes, take it out, and then put it in xylene to observe the lung tissue block until it is transparent;

2.1.6 Put in pre-melted 50% alcohol + 50% xylene for 30min, then put in pre-melted paraffin twice, 2h each time;

2.1.7 Put it into a pre-melted 100% paraffin carton to solidify, and store it at 4°C;

2.1.8 Use a microtome to cut the tissue into continuous slices with a thickness of 5-10 μM, and place the slices flat on a flat plate with the smooth side facing up;

2.1.9 Put the paraffin thin section on the water surface (water temperature 40℃), stretch it, and then stick it on the pre-treated glass slide;

2.1.10 Bake at 40℃ overnight for staining.

2.2 HE staining steps

2.2.1 Baking slices: placed in an 80°C incubator for 1 hour;

2.2.2 Dewaxing: dewaxing xylene I for 10 min, dewaxing xylene II for 20 min;

2.2.3 Dehydration: dehydrate twice in 100% ethanol for 5 min, dehydrate twice in 95% ethanol for 5 min, place in 85% ethanol for about 1 min, and place in 75% ethanol for about 1 min, and dry the liquid with absorbent paper;

2.2.4 Rinse: rinse with distilled water for 2 minutes, rinse twice;

2.2.5 Staining: hematoxylin staining for 5min;

2.2.6 Rinse slightly with tap water;

2.2.7 Differentiation: infiltrate with 1% hydrochloric acid alcohol solution for 5-10s (observe the slice from blue to red);

2.2.8 Back to blue: wash with tap water for about 25min;

2.2.9 0.5% eosin staining for 2min;

2.2.10 Dehydrate 2 times in 95% ethanol for 5 min, and dry the liquid with absorbent paper;

2.2.11 Dehydrate twice in 100% ethanol for 5 min, and dry the liquid with absorbent paper;

2.2.12 Transparent in xylene for 5min twice, and dry the liquid with absorbent paper;

2.2.13 Neutral gum sealing and observation under microscope.

2.3 Masson staining steps

2.3.1 Routine dewaxing of lung tissue sections to water;

2.3.2 Masson compound dyeing solution for 5-10min;

2.3.3 Immerse in 2% glacial acetic acid aqueous solution for a while;

2.3.4 Put in 1% phosphoric acid aqueous solution for 3 to 5 minutes and then spin dry;

2.3.5 Stain with aniline blue aqueous solution for 5min;

2.3.6 Alcohol gradient dehydration, Xylene I and II are transparent, and neutral gum is used for sealing.

2.4 Detection of MDA content in serum (thiobarbituric acid method)

2.4.1 Test principle: MDA (malondialdehyde) can combine with thiobarbituric acid (TBA) to form a red product. The product has an absorption maximum at 532 nm. Since the substrate of this reaction is TBA, this detection method is also called TBA method.

2.4.2 Operation steps:

(1) Set up blank tube, standard tube and measuring tube. Add 100 μl of absolute ethanol to the blank tube, add 100 μl of standard substance (tetraethoxypropane 10nmol/ml) to the standard tube, and add 100 μl of the sample to be tested to the measuring tube.

(2) Add 100 μl of Reagent 1, vortex and mix for 1 min.

(3) Add 1.5ml of Reagent 2 and Reagent 3 respectively and mix by vortexing.

(4) 95% constant temperature water bath for 40min, take out the test tube and cool with running water, centrifuge at 3500rpm for 10min at room temperature, suck the supernatant and add it to 96-well plate, 200μl per well, and set 3 duplicate wells for each sample. The OD value was measured at 532 nm, and the average value was taken as the measured OD value.

Zero with double distilled water.

*Because there is no hemolysis and lipid blood in the samples, only 2 samples are made in each batch of standard tubes and blank tubes, and blank tubes are used instead of control tubes. In this operation step, a kit was used for detection, and the kit was purchased from Nanjing Jiancheng Bioengineering Institute, model A003-1-2.

2.5 Detection of SOD content in serum (WST-1 method)

2.5.1 Operation steps

(1) Set control blank, control blank well, assay well and assay blank well, add 20 μl of double distilled water to the control well and control blank well, and add 20 μl of the sample to be tested to the assay well and assay blank well.

(2) Add 20 μl of enzyme diluent to the control blank wells and assay blank wells, and add 20 μl of enzyme working solution to the control wells and assay air.

(3) Add 200 μl of substrate application solution, vortex to mix, incubate at 37° C. for 20 min, and measure the OD value at 450 nm.

In this operation step, a kit was used for detection, and the kit was purchased from Nanjing Jiancheng Bioengineering Institute, model A001-3-2.

2.6 Detection of GSH content in serum (colorimetric method)

2.6.1 Operation steps

(1) Set blank wells, standard wells and assay wells, add 100 μl of reagent 1 (stock solution) to the blank wells, add 100 μl of standard (20 μM GSH standard solution) to the standard wells, and add 100 μl of the sample to be tested (supernatant) to the assay wells liquid).

(2) Add 100 μl of reagent two and 25 μl of reagent three, respectively.

(3) Mix well, let stand for 5 min, and measure the absorbance value of each well with a microplate reader at 405 nm.

In this operation step, a kit was used for detection, and the kit was purchased from Nanjing Jiancheng Bioengineering Institute, model A006-2-1.

3. Experimental results

3.1 Evaluation of the improvement effect of Artemisia annua on pulmonary fibrosis rats by HE staining of lung tissue

Figure 1 shows the effect of different concentrations of Artemisia annua on HE staining of bleomycin-induced pulmonary fibrosis in rats. As shown in Figure 1, the alveolar shape of the normal control group was normal, the wall was slender, and there was no inflammatory cell infiltration in the pulmonary interstitium. In the model control group, the alveolar septum thickened immediately after bleomycin administration, and inflammatory cell infiltration was seen; sheet-like consolidation was seen, with more inflammatory cell infiltration, fibroblast proliferation and collagen deposition in the consolidation area. In the Artemisia annua administration group (low-dose group, middle-dose group and high-dose group of Artemisia annua), it can be seen that inflammatory cell infiltration, alveolar septum thickening, fibroblast hyperplasia and collagen deposition were all affected by Artemisia annua administration. it has been improved.

3.2 Using Masson staining of lung tissue to evaluate the improving effect of Artemisia annua on pulmonary fibrosis in rats

Figure 2 shows the effect of different concentrations of Artemisia annua on Masson staining in bleomycin-induced pulmonary fibrosis rats.

As shown in Figure 2, the alveolar structure of the lung tissue of the rats in the normal control group was basically normal. In the model control group, different degrees of lung tissue fibrosis occurred in each group after bleomycin modeling. In the model control group, the alveoli of the lung tissue collapsed and fused, the alveolar wall widened, and the collagen fibers in the interstitium increased significantly. In the Artemisia annua administration group (the Artemisia annua low-dose group, the Artemisia annua medium-dose group, and the Artemisia annua high-dose group), the alveolar structure was partially destroyed, the alveolar walls were widened and thickened, and the collagen fibers increased. Compared with the model control group, the interstitial collagen fibers increased less in the Artemisia annua administration group. Artemisia annua low-dose group, Artemisia annua mid-dose group, and Artemisia annua high-dose group can significantly improve bleomycin-induced pulmonary fibrosis. The drug group was more effective.

3.3 Detection of SOD, GSH and MDA content in rat serum

Figure 3 is the result of detecting the content of SOD in rat serum in each group. Figure 4 shows the results of detecting the content of GSH in rat serum in each group. Figure 5 shows the results of detecting the content of MDA in rat serum in each group. Each group refers to the normal control group, the model control group, the low-dose group of Artemisia annua, the medium-dose group of Artemisia annua, the high-dose group of Artemisia annua and the positive control group.

In Figure 3, Figure 4 and Figure 5, ## represents a significant difference between the normal group and the model group, P<0.01, # represents a significant difference between the normal group and the model group, P<0.05, ** the administration group and the model group There was significant difference, P<0.01.

When the body is damaged, the system will produce a large number of oxygen free radicals. These oxygen free radicals then attack the polyunsaturated fatty acids in the biofilm, causing lipid peroxidation, forming lipid peroxides and new oxygen free radicals, etc., causing tissue and cell damage. MDA is a degradation product of lipid peroxidation, and its content can reflect the degree of lipid peroxidation in the body, and indirectly reflect the severity of cell or body damage.

Antioxidants are also used in the treatment of pulmonary fibrosis.

SOD has the ability to resist free radical damage, and the level of its activity can indirectly reflect the body's ability to scavenge oxygen free radicals and the severity of tissue oxidation. GSH (glutathione) is a system for scavenging free radicals in the body. In some pathological conditions, the activity of glutathione peroxidase will change significantly.

It can be seen from Figure 3 that the low-dose, middle-dose and high-dose groups of Artemisia annua can significantly increase the content of SOD. Among them, the effect of the middle-dose group and the high-dose group of Artemisia annua on improving SOD content exceeded that of the positive control group.

It can be seen from Figure 4 that the low-dose group, middle-dose group and high-dose group of Artemisia annua can slightly increase the content of GSH, which is obviously not as good as that of the positive control group.

It can be seen from Figure 5 that the middle-dose group of Artemisia annua can significantly reduce the content of MDA. Artemisia annua low-dose group could hardly reduce MDA content, Artemisia annua high-dose group could only slightly reduce MDA content, low-medium-high-dose group did not show a significant dose-effect relationship, which may be related to high-dose, high-dose drug. Too high a dose may reduce the effect on MDA.

The above results indicate that Artemisia annua can improve the degree of bleomycin-induced pulmonary fibrosis, and we preliminarily infer that the mechanism of improving pulmonary fibrosis may be related to antioxidant. And Artemisia annua high-dose group had the best effect in increasing SOD content, surpassing the results of the positive control group. The middle-dose group of Artemisia annua had the best effect in reducing the content of MDA.

The present invention is not limited to the above-mentioned embodiments, and any modifications, improvements and substitutions that can be conceived by those skilled in the art without departing from the essence of the present invention fall into the scope of the present invention.

Claims (7)

1. The purposes of Artemisia annua for the preparation of medicines for the treatment of pulmonary fibrosis, Described Artemisia annua is Artemisia annua extract; Described Artemisia annua extract is prepared by comprising the following steps: Soak the sieved Artemisia annua medicinal powder in water, heat and reflux for extraction 2 to 5 times, combine the water extracts, separate solid-liquid, and concentrate to obtain Artemisia annua extract; wherein, the amount of water each time is sieved. 8-16 times the quality of the powder of Artemisia annua L., the soaking time is 2-6 hours each time, and the extraction time is 2-6 hours each time. 2 . The use according to claim 1 , wherein the medicine forms a pharmaceutical preparation for treating pulmonary fibrosis, the pharmaceutical preparation comprises Artemisia annua and pharmaceutically acceptable excipients. 3 . 3. The use according to claim 2, wherein the Artemisia annua is the only active ingredient in the medicine for treating pulmonary fibrosis. 4. The use according to claim 3, wherein the medicament forms a pharmaceutical preparation for increasing the level of SOD in serum. 5. The use according to claim 4, wherein the medicament forms a pharmaceutical preparation for reducing the content of MDA in serum. 6 . The use according to claim 1 , wherein, in the pharmaceutical preparation of a unit dose, the amount of Artemisia annua L. extract is 0.89-4.6 g. 7 . 7 . The use according to claim 6 , wherein the amount of Artemisia annua L. extract is 1.8-4.3 g. 8 .

Images